Skip to main content
Premium Trial:

Request an Annual Quote

Compugen to Collaborate with Teva on Toxicity Biomarker Discovery

NEW YORK (GenomeWeb News) - Compugen today said it has signed a collaboration with Teva Pharmaceuticals to discovery biomarkers that could predict nephrotoxicity.
 
The agreement also may be expanded to include biomarker development for hepatoxicity and cardiotoxicity, Compugen said.
 
Under the agreement, Compugen will use its computational tools and nucleic acid testing technologies to analyze biological samples collected by Teva in a preclinical study.
 
Teva will have a license to use the discovered markers for its internal R&D programs, while Compugen has retained rights to license the markers to other companies, as well as rights for internal use.
 
Ana Cohen-Dayag, Compugen’s vice president of diagnostic biomarkers, said in a statement that the company will use predictive platforms it developed for immunoassay diagnostic collaborations to develop the biomarkers, which will enable early-stage identification of toxicity. 

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.